Cholesterol, astatination

Chloroxytrifluoromethane, 26 137-139 reactions, 26 140-143 addition to alkenes, 26 145-146 oxidative addition, 26 141-145 vibrational spectra, 26 139 Chloryl cation, 18 356-359 internal force constants of, 18 359 molecular structure of, 18 358, 359 properties of, 18 357, 358 synthesis of, 18 357, 358 vibrational spectra of, 18 358, 359 Chloryl compounds, reactions of, 5 61 Chloryl fluoride, 18 347-356 chemical properties of, 18 353-356 fluoride complexes of, 5 59 molecular structure of, 18 349-352 physical properties of, 18 352, 353 preparation, 5 55-57 and reactions, 27 176 properties of, 5 48 reactions, 5 58-61, 18 356 synthesis of, 18 347-349 thermal decomposition of, 18 354, 355 vapor pressures, 5 57, 18 353 vibrational spectra of, 18 349-352 Chloryl ion, 9 277 Cholegobin, 46 529 Cholesterol, astatination, 31 7 Cholorofluorphosphine, 13 378-380 h CHjPRj complexes, osmium, 37 274 Chromatium, HiPIP sequence, 38 249 Chromatium vinosum HiPIP, 38 108, 133 Fe4S4 + core, 33 60 Chromato complexes, osmium, 37 287... 

Ezetimibe is an antihyperlipidemic agent that inhibits absorption of cholesterol by the small intestine. It is indicated to be administered alone or with HMG-CoA reductase inhibitors as adjnnctive therapy to diet for reduction of elevated total cholesterol, LDL, and apolipoprotein (Apo) in patients with primary hypercholesterolemia with atorv-astatin or simvastatin for the reduction of elevated total cholesterol and LDL levels in patients with homozygous familial hypercholesterolemia as an adjunct to other lipidlowering treatments or if such treatments are unavailable and as adjnnctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygons familial sitosterolemia. 

---